サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：シェーグレン症候群の世界市場：2022年～2028年
市場調査レポート
商品コード
1078169

シェーグレン症候群の世界市場：2022年～2028年

Global Sjogren's syndrome Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 105 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
シェーグレン症候群の世界市場：2022年～2028年
出版日: 2022年04月23日
発行: Orion Market Research
ページ情報: 英文 105 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のシェーグレン症候群の市場規模は、予測期間中にCAGRで4.6％の大幅な成長が予測されています。市場を牽引している主な要因は、目の乾燥につながるコンタクトレンズの使用増加などです。

当レポートでは、世界のシェーグレン症候群市場について調査分析し、市場概要、セグメント別の市場分析、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 レポートサマリー

第2章 市場概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の発展
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界のシェーグレン症候群市場：タイプ別
    • 原発性シェーグレン症候群
    • 二次性シェーグレン症候群
  • 世界のシェーグレン症候群市場：薬剤別
    • ピロカルピン
    • シクロスポリン
    • ヒドロキシクロロキン
    • 免疫抑制剤
  • 世界のシェーグレン症候群市場：検査別
    • 血液検査
    • 視力検査
    • 画像検査
    • 生検

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • Argentis Pharmaceuticals, LLC
  • AstraZeneca
  • Aldeyra Therapeutics, Inc.
  • Bristol-Myers Squibb Co.
  • Biogen Inc.
  • DemconHemics BV.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Horizon Therapeutics
  • Johnson and Johnson Service Inc.
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • ONO PHARMACEUTICAL CO., LTD
  • Pfizer Inc.
  • RemeGen, Ltd.
  • Sanofi S.A
  • Sun Pharmaceutical Industries Ltd.
  • TearSolutions
図表

LIST OF TABLES

  • 1. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBALPRIMARY SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL SECONDARYSJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 5. GLOBALPILOCARPINE FOR SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL CYCLOSPORINE FORSJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL IMMUNOSUPPRESSIVE AGENTSFOR SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
  • 10. GLOBAL SJOGREN'S SYNDROME IN BLOOD TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL SJOGREN'S SYNDROME IN EYE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL SJOGREN'S SYNDROMEIN IMAGING TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL SJOGREN'S SYNDROMEIN BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 15. NORTH AMERICAN SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. NORTH AMERICAN SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
  • 19. EUROPEAN SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 21. EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 22. EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY DRUG TEST, 2021-2028 ($ MILLION)
  • 23. ASIA-PACIFIC SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 24. ASIA-PACIFIC SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TEST, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL SJOGREN'S SYNDROME MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL SJOGREN'S SYNDROME MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL SJOGREN'S SYNDROME MARKET, 2022-2028 (%)
  • 4. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBALPRIMARY SJOGREN'S SYNDROMEMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBALSECONDARYSJOGREN'S SYNDROMEMARKETSHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
  • 8. GLOBALPILOCARPINE FOR SJOGREN'S SYNDROMEMARKETSHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBALCYCLOSPORINE FOR SJOGREN'S SYNDROMEMARKETSHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN'S SYNDROME MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
  • 11. GLOBAL SJOGREN'S SYNDROMEMARKETSHARE BY TEST, 2021 VS 2028 (%)
  • 12. GLOBALSJOGREN'S SYNDROME IN BLOOD TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBALSJOGREN'S SYNDROME IN EYE TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBALSJOGREN'S SYNDROME IN IMAGING TEST MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBALSJOGREN'S SYNDROME IN BIOPSY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBALSJOGREN'S SYNDROMEMARKETSHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. US SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. CANADA SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. UK SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. FRANCE SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. GERMANY SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. ITALY SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. SPAIN SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF EUROPE SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. INDIA SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. CHINA SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. JAPAN SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. SOUTH KOREA SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD SJOGREN'S SYNDROME MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2018401

Global Sjogren Syndrome Market Size, Share & Trends Analysis Report By Type(Primary Sjogren's Syndrome, and Secondary Sjogren's Syndrome), by Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents)and by Test (Blood Test, Eye Test, Imaging Test, and Biopsy) Forecast Period (2022-2028)

The globalSjogren syndromemarket is anticipated to grow at a substantial CAGR of 4.6% during the forecast period.The market is mainly driven by a factor such as increased use of contact lenses which leads to dryness of the eyes. Moreover, high adoption of fast foods intakes with low calorie, vitamins, proteins, and nutritional values leads to unhealthy lifestyle adoption and that in turn become the enemy of immune diseases and the chance of growing Sjogren syndrome is increased and due to it the demand of the drugs and others treatments for this diseases Is also been increased.

The global Sjogren's syndromes market issegmented based ontype, drug type, and test. Based on type, the market is subdivided into primary sjogren's syndrome and secondary sjogren's syndrome. Based on a drug type, the market is sub-classified into pilocarpine, cyclosporine, hydroxychloroquine, and immunosuppressive agents. Based on thetest,the market is sub-segmented into blood tests, Eye tests, imaging tests, and biopsy.Among the test segment, the blood test sub-segment is expected to hold a prominent share in the market,as thesetests are routinely performed in the evaluation of a patient suffering from such Sjogren's syndrome as SS-A (Ro) and SS-B (La) antibodies, Antinuclear Antibody (ANA), Rheumatoid Factor, and others. Among all the Rheumatoid Factor Test is most commonly preferred due to RF being found in approximately half of the patients with the disease.

Geographically global Sjogren's syndromes market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.North American region is holding a prominent share owing to the growing number of autoimmune diseases that includes lupus, rheumatoid arthritis, dry mouth, and also increasing demand for advanced technological treatments solutions for these diseases. Moreover, increasing government initiatives in the region such as the North American Rheumatoid Arthritis Consortium has developed a plan to educate healthcare professionals and patients about the diagnosis and its treatment; attributed to such factors are contributing to the Sjogren's syndrome market growth in the region.

The major players that contribute to the growth of the global Sjogren's syndromesmarket include AbbVie Inc., Argentis Pharmaceuticals, LLC, AstraZeneca PLC, Bristol-Myers Squibb Co., Novartis International AG, Pfizer Inc., Sanofi S.A.,and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2021, Horizon Therapeutics plc. acquired Viela Bio, Inc. to Significantly Expand Development Pipeline Grow Rare Disease Medicine Portfolio, and Support Increased Scale Production. This agreement is mainly focused on autoimmune and severe inflammatory diseases in which companies will focus on UPLIZNA(autoimmune neuromuscular), VIB4920(Sjogren's syndrome and Phase 2), VIB7734(systemic lupus erythematosus), VIB1116(antibody for autoimmune diseases).

Research Methodology

The market study of the global Sjogren syndromemarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Sjogren Syndrome Market Research and Analysis by Type.

2. Global Sjogren Syndrome Market Research and Analysis by Drug Type.

3. Global Sjogren Syndrome Market Research and Analysis by Test.

The Report Covers

  • Comprehensive research methodology of the global Sjogren syndromemarket.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Sjogren syndromemarket.
  • Insights about market determinants that are stimulating the globalSjogren syndromemarket.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

Category-Pharmaceuticals

1. Report Summary

  • Current Product Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Sjogren's SyndromeMarket
  • Recovery Scenario of Global Sjogren's SyndromeMarket
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. ByRegion

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Sjogren's SyndromeMarket byType
    • 4.1.1. Primary Sjogren's Syndrome
    • 4.1.2. Secondary Sjogren's Syndrome
  • 4.2. Global Sjogren's Syndrome Market by Drug Type
    • 4.2.1. Pilocarpine
    • 4.2.2. Cyclosporine
    • 4.2.3. Hydroxychloroquine
    • 4.2.4. Immunosuppressive Agents
  • 4.3. Global Sjogren's Syndrome Market by Test
    • 4.3.1. Blood Test
    • 4.3.2. Eye Test
    • 4.3.3. Imaging Test
    • 4.3.4. Biopsy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. Argentis Pharmaceuticals, LLC
  • 6.4. AstraZeneca
  • 6.5. Aldeyra Therapeutics, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Biogen Inc.
  • 6.8. DemconHemics BV.
  • 6.9. Daiichi Sankyo Co., Ltd.
  • 6.10. Eisai Co., Ltd.
  • 6.11. F. Hoffmann-La Roche Ltd.
  • 6.12. Gilead Sciences, Inc.
  • 6.13. Horizon Therapeutics
  • 6.14. Johnson and Johnson Service Inc.
  • 6.15. Novartis International AG
  • 6.16. Otsuka Pharmaceutical Co., Ltd.
  • 6.17. ONO PHARMACEUTICAL CO., LTD
  • 6.18. Pfizer Inc.
  • 6.19. RemeGen, Ltd.
  • 6.20. Sanofi S.A
  • 6.21. Sun Pharmaceutical Industries Ltd.
  • 6.22. TearSolutions